VCU Researchers Develop VCU-1012 to Reduce Psychedelic Side Effects

The race to separate the therapeutic promise of psychedelic drugs from their harrowing perceptual side effects and physical discomforts has yielded a pair of notable developments in preclinical and clinical research. While traditional psychedelics have drawn intense interest for their potential to treat difficult mental health conditions, their clinical utility is frequently compromised by intense hallucinogenic trips, long durations, and unpleasant gastrointestinal reactions. Now, investigators are pursuing two distinct pathways to make these compounds medically viable: engineering molecules that bypass unwanted physical receptors entirely, and evaluating fast-dissolving delivery methods for depression.

Virginia Commonwealth University Researchers Deconstruct Quipazine to Build VCU-1012

At Virginia Commonwealth University, a team led by Małgorzata Dukat and Javier González-Maeso has tackled the physical side effects of psychedelics by re-engineering the psychedelic drug quipazine. While psychedelics hold potential for treating depression, anxiety, and post-traumatic stress disorder, they often trigger nausea by activating serotonin receptors located outside the brain.

To solve this, the research team systematically deconstructed quipazine, removing and modifying its structural features to pinpoint exactly how the molecule binds to different receptors. Quipazine features three nitrogen atoms in its chemical structure. By identifying the specific nitrogen responsible for binding to the serotonin 2A receptor, the team was able to rebuild the compound.

The researchers replaced quipazine’s quinoline core with a quinazoline unit containing an extra nitrogen atom. The resulting molecule, designated as VCU-1012, preserves quipazine-like affinity for the serotonin 2A receptor while completely eliminating activity at the serotonin 3 receptor, whose activation causes gastrointestinal distress.

When tested in mice exhibiting anxiety and depression-linked behaviors, VCU-1012 produced antidepressant-like effects without disrupting gastrointestinal function. Furthermore, the compound increased the density of dendritic spines—specialized neuron structures in the brain’s frontal cortex that represent a hallmark of enhanced neural plasticity.

Behavioral Screening Challenges and the Role of the Head-Twitch Response

Testing non-hallucinogenic psychedelic variants in rodents presents distinct scientific hurdles. Because mice cannot communicate their subjective experiences, researchers must rely on behavioral observation. A rapid side-to-side head movement known as the head-twitch response has long served as a proxy for altered perceptions and hallucinogenic potential, as it is triggered by substances like LSD and blocked by drugs targeting the 5HT2A serotonin receptor.

However, a recent study led by researchers at the University of Colorado Anschutz Medical Campus highlights the limitations of relying solely on the head-twitch response when screening novel compounds. Published in Translational Psychiatry, the findings indicate that this specific rodent behavior does not always serve as a reliable indicator of psychoactivity.

The research team compared LSD with lisuride, a structurally similar compound prescribed for Parkinson’s disease and hormonal imbalances that typically does not cause hallucinations. Tests showed that lisuride elevated stress hormone levels in mice and impaired their ability to solve cognitively challenging escape tasks, whereas LSD did not produce the same immediate task impairments or stress hormone spikes in those specific assays.

Thompson noted that while psychedelics offer transformative possibilities, they also produce complex alterations in consciousness characterized by abstract qualities such as oceanic boundlessness, ineffability, and transcendence of time and space. These intense subjective alterations can last for many hours and present clinical and economic hurdles, driving the search for safer alternatives.

Phase 3 Topline Results for DT120 in Major Depressive Disorder

While preclinical laboratories work on re-engineering molecules, late-stage clinical evaluations are simultaneously moving forward. Definium Therapeutics announced positive topline results from its Phase 3 EMERGE trial evaluating DT120, an orally disintegrating formulation of lysergide tartrate designed for adults suffering from major depressive disorder.

The trial enrolled 149 adults ranging from 18 to 74 years of age who met specific baseline severity thresholds. Participants were randomized to receive either a single 100-µg dose of DT120 or a placebo, entering a double-blind treatment phase lasting 12 weeks followed by a 40-week open-label extension.

According to data released by the company, the study successfully met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in depressive symptoms at week six as measured by the Montgomery-Åsberg Depression Rating Scale.

The fast-dissolving oral tablet aims to provide rapid absorption and lower gastrointestinal side effects compared to traditional oral LSD preparations. If subsequent peer-reviewed analyses confirm these findings, the therapeutic paradigm could shift psychiatry toward an episodic intervention model, akin to ketamine infusions or transcranial magnetic stimulation, where patients achieve durable relief from a single supervised dosing session rather than maintaining daily chronic medication schedules.